“We look forward to presenting preclinical data at ASGCT that underscore the potential of our in vivo HSC engineering platform to address complex genetic disorders and cancer,” said Robert Peters, ...

BOSTON--(BUSINESS WIRE)--Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing ...

Lead program advancing to IND filing in H1 2025 for the treatment of X-linked chronic granulomatous disease (X-CGD) will be first in vivo HSC-directed therapy tested in humans Preclinical data to be ...

Company’s Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment BOSTON--(BUSINESS WIRE)-- Ensoma, an in vivo hematopoietic stem cell (HSC) ...